Poxel Aktie [WKN DE: A14M04 / ISIN: FR0012432516]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Poxel SA

12.02.20		Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update (Businesswire)
12.02.20		Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress (Businesswire)
23.01.20		Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer (Businesswire)
08.01.20		Poxel Announces its Financial Calendar for 2020 (Businesswire)
19.12.19		Poxel Announces Participation at ODDO BHF Forum (Businesswire)
18.12.19		Poxel Announces Positive Results for PXL065 Phase 1b Trial and Provides Program Update (Businesswire)
26.11.19		Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan (Businesswire)
12.11.19		Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019 (Businesswire)
08.11.19		Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH (Businesswire)
07.11.19		Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019 (Businesswire)
05.11.19		Poxel Obtains Additional Funding to Advance Pipeline Programs (Businesswire)
18.09.19		Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
17.09.19		Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065 (Businesswire)
09.09.19		Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
04.09.19		Poxel Announces Participation at the H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
22.08.19		Poxel to Report Half Year Results for 2019 and Host Conference Call on August 26, 2019 (Businesswire)
05.08.19		Poxel Initiates Pharmacokinetic (PK)/ Pharmacodynamic (PD) Study as part of the Phase 2a Clinical Program for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
15.07.19		Poxel Reports Financial Update for Cash and Revenue for the Second Quarter and the First Half 2019 and Provides Corporate Update (Businesswire)
09.07.19		Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4 (Businesswire)
25.06.19		Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes (Businesswire)
21.05.19		Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society (Businesswire)
09.04.19		Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes (Businesswire)
08.04.19		Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial (Businesswire)
08.04.19		Poxel Announces First Quarter 2019 Financial Update (Businesswire)
01.04.19		Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
21.03.19		Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update (Businesswire)
18.03.19		Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference (Businesswire)
11.03.19		Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019 (Businesswire)
12.02.19		Poxel Announces Fourth Quarter and Full Year 2018 Financial Update (Businesswire)
07.01.19		Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference (Businesswire)
26.11.18		Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH (Businesswire)
12.11.18		Poxel Presents Promising Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting (Businesswire)
08.10.18		Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
04.10.18		Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress (Businesswire)
19.09.18		Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update (Businesswire)
13.09.18		Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K. (Businesswire)
30.08.18		Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs (Businesswire)
28.08.18		Poxel Announces Completion of Patient Enrollment for the TIMES 3 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
18.07.18		Poxel Announces Favorable Results for PXL770 Phase 1b Multiple Ascending Dose Trial and Drug-Drug Interaction Study (Businesswire)
10.07.18		Poxel Announces Second Quarter and First Half 2018 Financial Update (Businesswire)
25.06.18		New Imeglimin Data Demonstrating Pancreatic Beta-Cell Protection Presented at the American Diabetes Association 78th Scientific Sessions (Businesswire)
23.04.18		Poxel Announces First Quarter 2018 Financial Update (Businesswire)
04.04.18		Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference (Businesswire)
22.03.18		Poxel Provides Business Update and Reports Results for Full Year 2017 (Businesswire)
15.03.18		Poxel to Report Full Year 2017 Results on March 22, 2018 After Market Close and Host Conference Call at 7:00 PM CET (Paris time) / 2:00 PM EDT (New York time) (Businesswire)
13.03.18		Poxel Announces Initiation of TIMES 2 and TIMES 3 Trials for the Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
07.03.18		Poxel Announces Participation at the Cowen 38th Annual Healthcare Conference and Oppenheimer 28th Annual Healthcare Conference (Businesswire)
27.02.18		Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018 (Businesswire)
12.02.18		Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide (Businesswire)
22.01.18		Poxel Announces Fourth Quarter 2017 Financial Update (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Crash oder Rally: Das sind die Experten-Prognosen für Kryptowährungen wie Bitcoin, Ethereum & Co. im Jahr 2025

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.12.2024 07:38
Kaufwert:	EUR
	Hinzufügen Speichern